ClinicalTrials.gg
RecruitingNCT07318896AGARTROSISUpdated Jan 6, 2026

Effect of Agar/Collagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial

An interventional study of Agar-Agar and Agar-Agar and undenatured collagen type II in Osteearthritis, Joint Damage and Inflammation, sponsored by Fundació Eurecat. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Primary conditionInflammation(the registry's first term)UnverifiedIs this wrong?Inflammation is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Fundació Eurecat · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Joints-comprising bone, cartilage, ligaments, and synovial fluid-enable stable daily movement but may deteriorate with age, excess body weight, overuse, injury, or disease. Such degeneration, common from age 40 onward, underlies joint disorders like osteoarthritis, particularly in the knees, hips, hands, and spine, and is a major cause of chronic pain and disability. While antiinflammatory analgesics remain the standard approach to symptom control, they neither cure disease nor regenerate cartilage and can produce significant long-term adverse effects (gastrointestinal, hepatic, renal, and cardiovascular). These limitations motivate interest in natural or complementary strategies with safer profiles.

Within this context, marine algae, especially agar derived from red seaweed, have attracted attention for potential intestinal, metabolic, and joint benefits, aided by their fiber content. Another promising option is undenatured type II collagen (UC-II), the principal structural component of articular cartilage, whose endogenous production declines with age; clinical studies indicate that a daily intake of 40 mg UC-II can improve mobility, reduce pain, and enhance quality of life in individuals with osteoarthritis or exercise-related joint discomfort. Based on these considerations, an agar-agar supplement has been developed to relieve knee joint symptoms.

Read the detailed description

The primary objective of this study was to evaluate the effect of agar-agar (A-A), the combination of A-A with undenatured type II collagen (A+UC-II), and undenatured type II collagen (UC-II) on knee joint pain, assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), in subjects with mild to moderate joint pain without a diagnosis of osteoarthritis, compared with a control compound.

The secondary objectives were to evaluate the effects of A-A, A+UC-II, and UC-II consumption on:

  • Knee joint stiffness and functional capacity (subjective assessment).
  • Overall perception of knee health (subjective assessment).
  • Pain, stiffness, and functional capacity of the hand (subjective assessment).
  • Range of motion of the knee.
  • Functional capacity of the knee (objective assessment).
  • Functional capacity of the hand (objective assessment).
  • Frequency of medication use for joint pain relief (anti-inflammatories, analgesics).
  • Inflammatory blood markers.
  • Blood markers of collagen and bone metabolism.
  • Body composition.

The primary endpoint is patient-reported knee joint pain, assessed using the Pain subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire.

This is a randomized, placebo-controlled, triple-blind, parallel-group nutritional intervention with an allocation ratio of 1:1:1:1. A total of 80 participants (men and women) will be enrolled. Following a pre-screening visit to verify inclusion and exclusion criteria, eligible participants will be randomly assigned to one of four groups (n=20 per group) to consume, once daily for 12 weeks, one of the following products: agar-agar (A-A), A-A+UC-II (A+UC-II), UC-II alone, or placebo.

Each participant will complete three in-person visits and one interim telephone follow-up: a pre-screening visit (eligibility assessment), a baseline visit to initiate the intervention, a mid-study telephone follow-up, and an end-of-study visit. The total duration per participant will be 13 weeks.

The primary endpoint is patient-reported knee joint pain, assessed using the Pain subscale of the WOMAC questionnaire.

02

Conditions studied

  • Osteearthritis
  • Joint Damage
  • Inflammation
  • Cartilage Damage

Browse trials for

Keywords

  • Agar-Agar
  • undenatured collagen type II
  • Joint pain
  • knee pain
03

In context

Inflammation Unverified

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

This study's planned enrollment of 80 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Fundació Eurecat is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Compared within Inflammation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women between 40 and 70 years of age.
  • Submit a score of 6 to 10 out of 20 on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) knee pain questionnaire.
  • Sign the form.
  • Know how to read, write, and speak Spanish and/or Catalan.

Exclusion criteria

Exclusion Criteria:

  • Present (BMI) values \<18.5 kg/m\^2 or ≥30 kg/m\^2.
  • Present intolerances or allergies related to Agar-Agar, or any of the components of the products being evaluated, such as collagen or maltodextrin.
  • Take or have taken medications that may affect the study results. This is especially true for those who have been treated with oral or intra-articular within the 4 and 12 weeks prior to screening, respectively, or medications for osteoarthritis at the time of screening.
  • Patients who depend on prescription medications for pain control.
  • Take multivitamin or mineral supplements, collagen derivatives, or supplements containing bioactive compounds that may exert an anti-inflammatory effect, such as turmeric, ginger, omega-3, or polyphenol supplements.

(Individuals who consume multivitamin, mineral, or collagen-derived supplements or supplements will be eligible to participate in the study, provided they are willing to discontinue their intake for at least two weeks prior to the start of the study and throughout the entire study period).

  • Be an active smoker or have been one for less than 6 months.
  • Alcohol consumption:

    • Men: Consume 4 or more Standard Drink Units (SDU) daily or SDUs weekly.
    • Women: Consume 2 or more Standard Drink Units (SDU)* daily or SDUs weekly.
  • Have a diagnosis of osteoarthritis, active rheumatoid arthritis, and any inflammatory arthritic condition such as secondary inflammatory arthritis, gout, pseudogout, knee infection, marked angular deformities, or significant injury to the target joint within the 6 months prior to the start of the trial; arthroplasty and joint surgery of the target knee within the 2 years prior to the start of the study.
  • Have any gastrointestinal disease that affects the absorption of the compound and/or the study results, such as celiac disease, Crohn's disease, active cancer of any organ of the digestive or renal system, or hepatitis.
  • Be ineligible to participate in the study, according to the pre-screening evaluator's criteria.
  • Have lost 3 kg or more in the last 3 months.
  • Be pregnant or intend to become pregnant.
  • Be breastfeeding.
  • Be unable to follow the study guidelines.
  • Be participating or have participated in a clinical trial involving drug intervention or nutritional intervention within the last 30 days prior to inclusion in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Agar-Agar (A-A)

    Participants assigned to this group will receive agar-agar (A-A) supplementation and will take it for 12 weeks.

    Dietary Supplement: Agar-Agar

  • Experimental
    Agar-Agar + undenatured collagen type II (A+UC-II)

    Participants assigned to this group will receive agar-agar and undenatured collagen type II (A+UC-II) supplementation and will take it for 12 weeks.

    Dietary Supplement: Agar-Agar and undenatured collagen type II

  • Active comparator
    undenatured collagen type II (UC-II)

    Participants assigned to this group will receive undenatured collagen type II (UC-II) supplementation and will take it for 12 weeks.

    Dietary Supplement: undenatured collagen type II

  • Placebo comparator
    Placebo

    Participants assigned to this group will receive the placebo and will take it for 12 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementAgar-Agar

    2.4 g of agar-agar (Rhodophyceae group) presented in capsule form will be given.

    Also known as: (A-A)

  • Dietary supplementAgar-Agar and undenatured collagen type II

    2.4 g of agar- agar + 40 mg of undenatured collagen type II, presented in capsule form will be given.

    Also known as: (A+UC-II)

  • Dietary supplementundenatured collagen type II

    40 mg of undenatured collagen type II + 2.4 g of maltodextrin will be given in capsule form

    Also known as: (UC-II)

  • Dietary supplementPlacebo

    2.4 g Maltodextrin will be given in capsule form

06

What researchers measure

Primary outcomes

  1. Change in perception of knee joint pain.

    This will be determined using the pain subscale of the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire. The questionnaire assesses clinically meaningful changes in symptoms and physical disability in individuals with osteoarthritis or those experiencing joint discomfort. It evaluates the perceived intensity of knee pain using the Likert scale (0: no pain; 1: mild pain; 2: moderate pain; 3: severe pain; 4: extreme pain).

    Time frame: Before (baseline), during (6 weeks) and after treatment period (12 weeks).

Secondary outcomes

  1. Body weight.

    Body weight will be measured by Tanita TBF-300 (Body Composition Analyzer, Brooklyn NY, USA) as a descriptive variable.

    Time frame: at week 1.

  2. Height.

    Height will be measured by standardized method.

    Time frame: At week 1.

  3. Body mass index (BMI) (kg/m^2).

    BMI will be determined using the Tanita TBF-300 (Body Composition Analyzer, Brooklyn, NY, USA) as a descriptive variable.

    Time frame: At week1.

  4. Age.

    Age will be recorded in years.

    Time frame: At week 1.

  5. Changes in systolic and diastolic blood pressure and resting heart rate.

    It will be measured using an automatic sphygmomanometer.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  6. Changes in body weight.

    Body weight will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  7. Change in BMI.

    Weight and height will be combined to report BMI in kg/m\^2.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  8. Changes in the amount of body fat.

    Body fat in kg will be measured with Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  9. Changes in the amount of body fat.

    Body fat percentage will be measured with Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  10. Changes in the amount of muscle mass.

    Muscle mass in kg will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  11. Changes in the amount of muscle mass.

    Muscle mass percentage will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  12. Changes in the amount of bone mass.

    Bone mass (kg) will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  13. Changes in the amount of total body water.

    Total body water (Kg) will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  14. Change in the amount of lean mass.

    The total lean mass (Kg) will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  15. Changes in bone mineral content.

    This will be measured, in Kg, by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  16. Changes in segmental impedance.

    This will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  17. Changes in segmental phase angle.

    The phase angle (kHz) will be measured by Inbody 970.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  18. Change in perception of knee joint stiffness.

    This variable will be assessed using the rigidity subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire. It consists of two items. The perceived intensity of knee stiffness will be evaluated in two different situations: in the morning, immediately after waking up, and during the day, following a period of rest or inactivity, using the Likert scale (0: no stiffness; 1: mild stiffness; 2: moderate stiffness; 3: severe stiffness; 4: extreme stiffness) (total scale 0-8).

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  19. Change in perception of knee functional capacity.

    This variable will be assessed using the rigidity subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire. It consists of 17 items. The difficulty in performing various activities-such as climbing or descending stairs, walking, bending, or carrying out daily tasks-will be evaluated using the Likert scale (0: no difficulty; 1: mild difficulty; 2: moderate difficulty; 3: severe difficulty; 4: extreme difficulty) (total scale 0-68).

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  20. Changes in the perception of the general health status of the knee

    This variable will be assessed using the rigidity subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire. It will be obtained by summing the scores of the three subscales: pain, stiffness, and physical function. The total score ranges from 0 to 96, reflecting the best and worst possible knee condition, respectively.

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  21. Perception of pain in the hand joint

    This variable will be assessed using the pain subscale of the Australian-Canadian Hand Osteoarthritis Index (AUSCAN) questionnaire. The questionnaire consists of 5 items that assess, over the previous 48 hours, the intensity of pain at rest and while grasping, lifting, turning, and squeezing objects, using a Likert scale (0: no pain; 1: mild pain; 2: moderate pain; 3: severe pain; 4: extreme pain).

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  22. Changes in perception of hand joint stiffness

    This variable will be assessed using the pain subscale of the Australian-Canadian Hand Osteoarthritis Index (AUSCAN) questionnaire. It consists of 1 item that assesses, over the previous 48 hours, the intensity of hand stiffness upon waking, using a Likert scale (0: no stiffness; 1: mild stiffness; 2: moderate stiffness; 3: severe stiffness; 4: extreme stiffness).

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  23. Changes in perception of the functional capacity of the hand joint

    This variable will be assessed using the pain subscale of the Australian-Canadian Hand Osteoarthritis Index (AUSCAN) questionnaire. It consists of 7 items that assess, over the previous 48 hours, the difficulty in turning, holding, opening, carrying, grasping, and squeezing various objects with the hand, using a Likert scale (0: no difficulty; 1: mild difficulty; 2: moderate difficulty; 3: severe difficulty; 4: extreme difficulty).

    Time frame: Before (baseline) during ( 6 weeks) and after treatment period (12 weeks).

  24. Changes in knee range of motion

    This variable will be measured using a digital goniometer.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  25. Changes in the functional capacity of the hand joints

    Hand grip strength will be measured, in kilograms, using the InGrip digital dynamometer.

    Time frame: Before (baseline), and after treatment period (12 weeks)

  26. Changes in the speed when going up and down stairs.

    This variable will measured by The "Stair Climb Test" , in which the volunteer must climb and descend 10 standard steps (between 15 and 20 cm) without the aid of a handrail. The time (minutes and seconds) taken by the volunteer to complete the test will be recorded.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  27. Changes in pain perception at the end of the Stair Climb Test

    At the end, perceived pain will be measured using a 100 mm visual analog scale, where 0 indicates "no pain" and 100 indicates "all the pain you can experience".

    Time frame: Before (baseline) and after treatment period (12 weeks).

  28. Changes in plasma interleukin 6 (IL-6) concentration.

    Plasma IL-6 levels will be measured by ELISA kits

    Time frame: Before (baseline) and after treatment period (12 weeks).

  29. Changes in plasma tumor necrosis alpha (TNF-a) concentration.

    Plasma TNF-a levels will be measured by ELISA kit.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  30. Changes in plasma monocyte chemotactic protein 1 (MCP-1) concentration

    Plasma MCP-1 levels will be measured ELISA kit.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  31. Changes in serum High-sensitivity C-reactive protein (hsCRP) concentration.

    Serum hsCRP levels will be measured by chemiluminescence method.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  32. Changes in serum levels of C-terminal telopeptide of type 1 collagen (CTX1).

    Serum CTX1 will be measured by electrochemiluminescence method.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  33. Changes in serum levels of N-terminal propeptide of type I collagen (PINP).

    Serum PINP will be measured by electrochemiluminescence method.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  34. Changes in serum levels of hyaluronic acid (HA).

    Serum HA will be measured by ELISA kits.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  35. Changes in serum levels of cartilage oligomeric matrix protein (COMP).

    Serum COMP will be measured by ELISA kits.

    Time frame: Before (baseline) and after treatment period (12 weeks).

  36. Dietary control.

    The intake of foods containing bioactive components that could alleviate pain will be assessed using an adapted food frequency questionnaire. The following scale will be used: "I have not used it"; "1 time a week"; "2-4 times a week"; "5-6 times a week"; "7-10 times a week"; "10-20 times a week"; "\>20 times a week"

    Time frame: Before (baseline), during (6 week) and after treatment period (12 weeks).

  37. Changes in dietary supplement use.

    The consumption of supplements and dietary products by the volunteers will be monitored through the analysis of the supplement and dietary product records in the case report form.

    Time frame: Before (baseline), during (6 week) and after treatment period (12 weeks).

  38. Changes in concomitant medications.

    The consumption of concomitant medication will be monitored through the analysis of the concomitant medication records in the case report form.

    Time frame: Before (baseline), during (6 week) and after treatment period (12 weeks).

  39. Changes in pain-relieving medication use.

    This will be assessed by recording concomitant medications in the data collection form.

    Time frame: Before (baseline), during (6 week) and after treatment period (12 weeks).

  40. Physical activity levels.

    This will be determined by analyzing the Physical Activity Questionnaire, Quick Physical Activity Classifier, adapted from the Generality of Catalonia (PEFS) guidelines.

    Time frame: Before (baseline), and after treatment period (12 weeks).

  41. Monitoring of adverse effects.

    The presence of adverse events reported by the participant in the data collection form will be recorded using the Adverse Effects Form.

    Time frame: During (6 week) and after treatment period (12 weeks).

  42. Treatment adherence rate.

    Treatment adherence will be calculated using the following formula: (number of capsules the volunteer should have taken / number of capsules actually taken) \* 100

    Time frame: During (6 week) and after treatment period (12 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Jan 6, 2026
StartActual
Nov 10, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07318896
Lead sponsor
Fundació Eurecat
Collaborators
HISPANAGAR SA
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Nov 10, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Antoni Caimari Palou, PhD
Contact
antoni.caimari@eurecat.org
0034 977 300 805
Anna Crescenti, PhD
Contact
anna.crescenti@eurecat.org
0034 977 300 431
Antoni Caimari Palou, PhD
principal investigator · UTNS (Eurecat, Reus)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion